Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
J Antimicrob Chemother ; 78(5): 1137-1142, 2023 05 03.
Article in English | MEDLINE | ID: mdl-36883591

ABSTRACT

The ongoing spread of antimicrobial resistance has made the treatment of uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea increasingly difficult. New oral treatment options are urgently needed. Gepotidacin (previously GSK2140944) is a novel, bactericidal, oral, 'first-in-class' triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking two essential topoisomerase enzymes. Mutations in both enzymes would likely be necessary for resistance to occur, thus raising hopes that the drug will be able to maintain long-term effectiveness. Data from Phase II clinical trials of gepotidacin in UTIs and urogenital gonorrhoea appear promising, and Phase III trials are underway. In this review we summarize the development of gepotidacin and discuss its potential role in clinical practice. If approved, gepotidacin will be the first new oral antibiotic for UTIs in more than 20 years.


Subject(s)
Gonorrhea , Urinary Tract Infections , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Gonorrhea/drug therapy , Gonorrhea/microbiology , Acenaphthenes/therapeutic use , Acenaphthenes/pharmacology , Urinary Tract Infections/drug therapy
2.
Sex Transm Infect ; 99(1): 64-69, 2023 02.
Article in English | MEDLINE | ID: mdl-36411033

ABSTRACT

BACKGROUND: Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is active against most strains of Neisseria gonorrhoeae (N. gonorrhoeae). Phase II data suggested higher exposures were needed for efficacy and to suppress resistance development. A translational approach using in vitro pharmacokinetic/pharmacodynamic (PK/PD) and clinical data was used to select a gepotidacin dose for a phase III study. In this narrative review of previously shown data, we summarise how a translational approach based on in vitro PK/PD and population PK modelling and simulation data was undertaken to select a dosing regimen for the ongoing phase III gepotidacin study in participants with uncomplicated urogenital gonorrhoea. METHODS: For dose selection, prior in vitro minimum inhibitory concentrations (MICs) and PK/PD data were available. PK modelling was conducted to determine a dose that would limit plasma concentrations to less than 14 µg/mL (as concentrations above this are associated with QT prolongation and effects associated with acetylcholinesterase inhibition) while maintaining ≥90% probability of target attainment (PTA) for efficacy and resistance suppression against N. gonorrhoeae isolates with gepotidacin MICs ≤1 µg/mL. RESULTS: Two 3000 mg gepotidacin doses, administered 10-12 hours apart, resulted in PTA of ≥97.5% and ≥91.7% for gepotidacin MICs ≤1 µg/mL for the ratio of the area under the free drug plasma concentration-time curve over 24 hours to the MIC (fAUC0-24/MIC) efficacy, and resistance suppression targets of 40 and 46, respectively, but limited the occurrence of maximum plasma concentrations ≥14 µg/mL. CONCLUSIONS: Two gepotidacin 3000 mg oral doses 10-12 hours apart provide ~2-fold higher systemic exposures, increase efficacy for higher gepotidacin MIC N. gonorrhoeae isolates, reduce resistance potential and limit plasma concentrations of potential safety concern, compared with higher doses.


Subject(s)
Gonorrhea , Humans , Gonorrhea/drug therapy , Gonorrhea/microbiology , Acetylcholinesterase/pharmacology , Acetylcholinesterase/therapeutic use , Anti-Bacterial Agents/therapeutic use , Acenaphthenes/pharmacology , Acenaphthenes/therapeutic use , Neisseria gonorrhoeae , Microbial Sensitivity Tests , Clinical Trials, Phase III as Topic
3.
Biomolecules ; 11(10)2021 09 25.
Article in English | MEDLINE | ID: mdl-34680037

ABSTRACT

The evidence that telomerase is overexpressed in almost 90% of human cancers justifies the proposal of this enzyme as a potential target for anticancer drug design. The inhibition of telomerase by quadruplex stabilizing ligands is being considered a useful approach in anticancer drug design proposals. Several aromatic ligands, including porphyrins, were exploited for telomerase inhibition by adduct formation with G-Quadruplex (GQ). 5,10,15,20-Tetrakis(N-methyl-4-pyridinium)porphyrin (H2TMPyP) is one of the most studied porphyrins in this field, and although reported as presenting high affinity to GQ, its poor selectivity for GQ over duplex structures is recognized. To increase the desired selectivity, porphyrin modifications either at the peripheral positions or at the inner core through the coordination with different metals have been handled. Herein, studies involving the interactions of TMPyP and analogs with different DNA sequences able to form GQ and duplex structures using different experimental conditions and approaches are reviewed. Some considerations concerning the structural diversity and recognition modes of G-quadruplexes will be presented first to facilitate the comprehension of the studies reviewed. Additionally, considering the diversity of experimental conditions reported, we decided to complement this review with a screening where the behavior of H2TMPyP and of some of the reviewed metal complexes were evaluated under the same experimental conditions and using the same DNA sequences. In this comparison under unified conditions, we also evaluated, for the first time, the behavior of the AgII complex of H2TMPyP. In general, all derivatives showed good affinity for GQ DNA structures with binding constants in the range of 106-107 M-1 and ligand-GQ stoichiometric ratios of 3:1 and 4:1. A promising pattern of selectivity was also identified for the new AgII derivative.


Subject(s)
Acenaphthenes/therapeutic use , Neoplasms/drug therapy , Porphyrins/therapeutic use , Telomerase/antagonists & inhibitors , Acenaphthenes/chemistry , Antineoplastic Agents/therapeutic use , Binding Sites/drug effects , G-Quadruplexes/drug effects , Humans , Ligands , Porphyrins/chemistry , Telomerase/genetics
4.
Sex Health ; 16(5): 449-456, 2019 09.
Article in English | MEDLINE | ID: mdl-31292063

ABSTRACT

Neisseria gonorrhoeae, the causative agent of gonorrhoea, has rapidly evolved from an exquisitely susceptible pathogen into a 'superbug' with the capacity to exhibit an extensively drug resistant (XDR) phenotype. The threat of untreatable gonorrhoea now looms on the horizon while the arsenal of effective antimicrobial agents diminishes with time. Ceftriaxone remains the mainstay of first-line therapy as a single agent or as the backbone of a dual therapy regimen. The implementation of new assays to facilitate 'precision' treatment, based on the prediction of N. gonorrhoeae susceptibility to old anti-gonococcal drugs, may enable sparing use of ceftriaxone in those countries that can afford this technology. A few existing drugs, such as ertapenem, can be repositioned to help manage multi-drug resistant and XDR gonorrhoea. Recent clinical trials involving solithromycin and delafloxacin have generated disappointing results in that both agents failed to show non-inferiority to conventional ceftriaxone-based regimens. At present, zoliflodacin and gepotidacin appear to be the most promising antimicrobial agents in clinical development. Both drugs performed well in eradicating urogenital gonorrhoea in recent Phase 2 trials; however, treatment failures were reported at the oropharyngeal site, which is an important site of infection in men who have sex with men and sex workers. Given this observation, it is unlikely that either of these new agents could be promoted for monotherapy of gonorrhoea. The pre-clinical pipeline remains relatively empty of agents likely to progress to clinical development for gonorrhoea treatment and increased investment into gonorrhoea-specific drug discovery is recommended.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Gonorrhea/drug therapy , Neisseria gonorrhoeae/drug effects , Acenaphthenes/therapeutic use , Barbiturates/therapeutic use , Drug Development , Drug Resistance, Multiple, Bacterial , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Isoxazoles , Macrolides/therapeutic use , Morpholines , Oxazolidinones , Spiro Compounds/therapeutic use , Triazoles/therapeutic use
5.
Article in English | MEDLINE | ID: mdl-31061153

ABSTRACT

Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has in vitro activity against a range of bacterial pathogens, including Escherichia coli Urinary tract infections often progress to pyelonephritis and are a worldwide problem due to the prevalence of multidrug-resistant E. coli strains. This study evaluated the in vivo efficacy of gepotidacin against four strains of multidrug-resistant E. coli in a rat pyelonephritis model. Infected rats received controlled intravenous infusions of gepotidacin every 12 h for 4 days that recreated human systemic exposures from oral gepotidacin (800 or 1,500 mg twice daily for 4 days). Liquid chromatography-tandem mass spectrometry analysis of blood samples and kidney homogenates showed that gepotidacin levels were 6- to 7-fold higher in kidneys than in blood. Across experiments with 4-day gepotidacin treatments, bacterial CFU in kidneys were reduced by 2.9 to 4.9 log10 compared to pretreatment levels, and bladder CFU were reduced to the lower limit of detection (1.2 log10). The efficacies of 800- and 1,500-mg gepotidacin exposures were statistically similar. A time-course experiment indicated that a period of more than 24 h of gepotidacin treatment was required for efficacy and that 4 days were needed for maximal response. Overall, these results demonstrate that the recreated human exposures of gepotidacin studied were effective in an animal model of pyelonephritis caused by multidrug-resistant E. coli and that further evaluation for clinical use is warranted.


Subject(s)
Acenaphthenes/therapeutic use , Anti-Bacterial Agents/therapeutic use , Escherichia coli/drug effects , Escherichia coli/pathogenicity , Heterocyclic Compounds, 3-Ring/therapeutic use , Pyelonephritis/drug therapy , Animals , Humans , Kidney/drug effects , Kidney/metabolism , Male , Microbial Sensitivity Tests , Pyelonephritis/microbiology , Rats , Rats, Sprague-Dawley
6.
Article in English | MEDLINE | ID: mdl-28373199

ABSTRACT

Gepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial agent which has in vitro activity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs). This phase 2, randomized, 2-part, multicenter, dose-ranging, response-adaptive study with optional intravenous-oral switch evaluated the efficacy and safety of gepotidacin for the treatment of Gram-positive ABSSSIs in 122 adult patients in the United States. The study had a double-blind phase (part 1; intravenous [750 mg or 1,000 mg every 12 h {q12h}]) and an open-label phase (part 2; intravenous [750 mg q12h, 1,000 mg q12h, or 1,000 q8h]). The primary endpoint was a composite of efficacy and safety which consisted of the early cure rate and the withdrawal rate due to drug-related adverse events and utilized a clinical utility index for dose selection. At the early efficacy visit (48 to 72 h after the first dose), the 750-mg q12h and 1,000-mg q8h groups met prespecified success criteria for clinical utility in terms of efficacy and safety; however, the 1,000-mg q12h group did not meet these criteria due to observed lower efficacy rates. The most frequently reported adverse events were nausea (20%) and diarrhea (13%). These encouraging phase 2 results demonstrate the potential for gepotidacin to meet the medical need for novel antibacterial agents to treat ABSSSIs due to drug-resistant pathogens through a unique mechanism of action. (This study has been registered at ClinicalTrials.gov under registration no. NCT02045797.).


Subject(s)
Acenaphthenes/therapeutic use , Anti-Bacterial Agents/therapeutic use , Gram-Positive Bacteria/pathogenicity , Heterocyclic Compounds, 3-Ring/therapeutic use , Skin Diseases, Bacterial/drug therapy , Adult , Female , Gram-Positive Bacteria/drug effects , Humans , Male , Middle Aged , Skin Diseases, Bacterial/microbiology
7.
Anticancer Res ; 35(9): 4599-604, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26254348

ABSTRACT

BACKGROUND: Pancreatic cancer is a highly lethal cancer due to early metastasis and resistance to current chemotherapeutic agents. Abnormal protein kinase B (AKT) activation is an important mechanism of chemoresistance to gemcitabine, the most widely used agent in pancreatic cancer. MATERIAL AND METHODS: In the study, we tested the hypothesis that combining an AKT inhibitor with gemcitabine would augment anti-tumor activity. We treated human pancreatic cancer MiaPaCa-2 cells with gemcitabine and the AKT inhibitor triciribine, alone and in combination, and evaluated treatment effects using trypan blue assay, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium (MTT) assay, and cell death enzyme-linked immunosorbant assay. Colorimetric data of MTT assay were computationally analyzed for synergism of the combination therapy by CalcuSyn2 (Biosoft, Great Shelford, Cambridge, UK). RESULTS: Both gemcitabine and triciribine inhibited cell growth in a dose-dependent manner. Triciribine synergistically enhanced the cytotoxic activity of gemcitabine. The combination index (CI) provides the synergistic, additive, or antagonistic effects of the two-drug combination. CI at the 50% effective dose at 1:500 ratio of gemcitabine to triciribine was 0.74, indicating the synergistic effect of the drugs. The combination treatment with the non-apoptotic dose of each agent distinctly induced apoptosis, with gemcitabine in combination with triciribine, synergistically inhibiting pancreatic cancer cell growth and inducing apoptosis. CONCLUSION: These findings support the use of triciribine to overcome activated AKT-mediated resistance of pancreatic cancer to gemcitabine.


Subject(s)
Acenaphthenes/therapeutic use , Deoxycytidine/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Ribonucleotides/therapeutic use , Acenaphthenes/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/drug effects , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Deoxycytidine/pharmacology , Deoxycytidine/therapeutic use , Dose-Response Relationship, Drug , Drug Synergism , Humans , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/pathology , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-akt/metabolism , Ribonucleotides/pharmacology , Staining and Labeling , Trypan Blue/metabolism , Gemcitabine
8.
Neuropharmacology ; 72: 29-37, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23624287

ABSTRACT

The exacerbation of musculoskeletal pain by stress in humans is modeled by the musculoskeletal hyperalgesia in rodents following a forced swim. We hypothesized that stress-sensitive corticotropin releasing factor (CRF) receptors and transient receptor vanilloid 1 (TRPV1) receptors are responsible for the swim stress-induced musculoskeletal hyperalgesia. We confirmed that a cold swim (26 °C) caused a transient, morphine-sensitive decrease in grip force responses reflecting musculoskeletal hyperalgesia in mice. Pretreatment with the CRF2 receptor antagonist astressin 2B, but not the CRF1 receptor antagonist NBI-35965, attenuated this hyperalgesia. Desensitizing the TRPV1 receptor centrally or peripherally using desensitizing doses of resiniferatoxin (RTX) failed to prevent the musculoskeletal hyperalgesia produced by cold swim. SB-366791, a TRPV1 antagonist, also failed to influence swim-induced hyperalgesia. Together these data indicate that swim stress-induced musculoskeletal hyperalgesia is mediated, in part, by CRF2 receptors but is independent of the TRPV1 receptor.


Subject(s)
Hyperalgesia/etiology , Hyperalgesia/metabolism , Musculoskeletal Pain/etiology , Musculoskeletal Pain/metabolism , Receptors, Corticotropin-Releasing Hormone/metabolism , TRPV Cation Channels/metabolism , Acenaphthenes/therapeutic use , Analgesics/therapeutic use , Analysis of Variance , Animals , Body Weight/drug effects , Cold Temperature/adverse effects , Disease Models, Animal , Diterpenes/therapeutic use , Female , Hyperalgesia/drug therapy , Mice , Morphine/therapeutic use , Muscle Strength/drug effects , Pain Measurement , Peptide Fragments/therapeutic use , Peptides, Cyclic/therapeutic use , Reaction Time/drug effects , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Swimming/psychology , TRPV Cation Channels/antagonists & inhibitors
9.
J Pharmacol Sci ; 119(4): 330-40, 2012.
Article in English | MEDLINE | ID: mdl-22814102

ABSTRACT

Mcl-1, an anti-apoptotic Bcl-2 homolog that has a structurally divergent BH3-binding pocket, non-redundant action model, and unique characteristic of short life confers complete resistance to the BH3 mimetic ABT-737. Herein, we used S1, previously identified as a Mcl-1/Bcl-2 dual inhibitor and a pure BH3 mimetic, to explore the mechanism of Mcl-1's action and supply a strategy to challenge Mcl-1's protection. Apoptosis assay in SMMC-7721, HCT116, and K562 cells demonstrated that S1 can effectively challenge Mcl-1's anti-apoptotic effect. Notably, we discovered an unexpected dynamic change of Mcl-1 that directly correlates with resistance or commitment to apoptosis induced by both ABT-737 and S1. Co-immunoprecipitation assays demonstrated that Mcl-1 increase results from Bim trafficking from Bcl-2 to Mcl-1, while subsequent Bak released by S1 determines Mcl-1 decrease and full-blown apoptosis. Further experiments using Bak shRNA testified that Bak accounts for S1-induced apoptosis and Mcl-1 decrease. Consistently, Bax-deficient DU145 cells are sensitive to S1, whereas Bak-mutant MKN-28 cells are significantly more resistant. The in vitro model could be extended to an in vivo mouse xenograft model in which Mcl-1 confers resistance by increased protein level, and the release of Bak could serve as a biomarker of apoptosis.


Subject(s)
Acenaphthenes/pharmacology , Antineoplastic Agents/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrroles/pharmacology , bcl-2 Homologous Antagonist-Killer Protein/metabolism , Acenaphthenes/therapeutic use , Animals , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Biphenyl Compounds/pharmacology , Cell Line, Tumor , Humans , Mice , Mice, Inbred BALB C , Myeloid Cell Leukemia Sequence 1 Protein , Neoplasms/drug therapy , Neoplasms/pathology , Nitrophenols/pharmacology , Peptide Fragments , Piperazines/pharmacology , Proto-Oncogene Proteins , Proto-Oncogene Proteins c-bcl-2/genetics , Pyrroles/therapeutic use , Sulfonamides/pharmacology , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
10.
Neuropsychopharmacology ; 32(9): 1941-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17287823

ABSTRACT

There is an extensive evidence that corticotropin releasing factor (CRF) is hypersecreted in depression and anxiety, and blockade of CRF could have therapeutic benefit. We report preclinical data and the results of a clinical Phase I study with the novel nonpeptide CRF(1) antagonist NBI-34041/SB723620. Preclinical data conducted with different cell lines expressing human CRF receptors and in Wistar and Sprague-Dawley rats indicate that NBI-34041 is effective in reducing endocrine responses to pharmacological and behavioral challenge mediated by CRF(1) receptors. These specific properties and its well-documented safety profile enabled a clinical Phase I study with 24 healthy male subjects receiving NBI-34041 (10, 50, or 100 mg) or placebo for 14 days. Regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis was evaluated by intravenous stimulation with 100 microg of human CRF. Psychosocial stress response was investigated with the Trier Social Stress Test (TSST). Treatment with NBI-34041 did not impair diurnal adrenocorticotropic hormone (ACTH) and cortisol secretion or CRF evoked ACTH and cortisol responses but attenuated the neuroendocrine response to psychosocial stress. These results suggest that NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress. NBI-34041 demonstrates that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders.


Subject(s)
Corticotropin-Releasing Hormone/therapeutic use , Drug Evaluation, Preclinical , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Receptors, Corticotropin-Releasing Hormone/physiology , Stress, Psychological/drug therapy , Acenaphthenes/therapeutic use , Adrenocorticotropic Hormone/blood , Analysis of Variance , Animals , Autoradiography , Cell Line , Corticotropin-Releasing Hormone/pharmacology , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Double-Blind Method , Emotions/drug effects , Humans , Hydrocortisone/blood , Male , Rats , Rats, Sprague-Dawley , Time Factors
11.
Bioorg Med Chem Lett ; 15(16): 3713-6, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-15946843

ABSTRACT

Two isomers of the hexahydro-tetraazaacenaphthylene templates (1 and 2) are presented as novel, potent, and selective corticotropin releasing factor-1 (CRF1) receptor antagonists. In this paper, we report the affinity and SAR of a series of compounds, as well as pharmacokinetic characterization of a chosen set. The anxiolitic activity of a selected example (2ba) in the rat pup vocalization model is also presented.


Subject(s)
Acenaphthenes/pharmacology , Acenaphthenes/therapeutic use , Anxiety/drug therapy , Depression/drug therapy , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Acenaphthenes/chemical synthesis , Animals , Disease Models, Animal , Drug Evaluation, Preclinical , Molecular Structure , Rats , Rats, Wistar , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...